| Date | Time | Source | Headline | Symbol | Company |
| 06/06/2016 | 7:35AM | Business Wire | ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate & 12.9-Month Median Pro... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/04/2016 | 7:35AM | Business Wire | ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Mon... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/04/2016 | 7:35AM | Business Wire | ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatin... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/02/2016 | 8:31AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/02/2016 | 7:35AM | Business Wire | ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig® | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/01/2016 | 4:55PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/01/2016 | 4:53PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 06/01/2016 | 7:35AM | Business Wire | ARIAD to Present at the Jefferies 2016 Global Healthcare Conference | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/31/2016 | 7:35AM | Business Wire | ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR & HER2, in Patie... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/27/2016 | 5:16PM | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/26/2016 | 4:09PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/25/2016 | 4:05PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/24/2016 | 9:25AM | Business Wire | ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/20/2016 | 9:28AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/19/2016 | 4:12PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/19/2016 | 7:35AM | Business Wire | ARIAD Announces Pricing and Reimbursement for Iclusig in France | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/18/2016 | 5:08PM | Business Wire | ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/13/2016 | 6:01PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/10/2016 | 5:11PM | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/10/2016 | 11:01AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/10/2016 | 8:16AM | Business Wire | Incyte y ARIAD anuncian un acuerdo según el cual Incyte adquiere los derechos de licencia de Iclusig® (ponatinib) y las ope... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/10/2016 | 7:46AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/10/2016 | 7:35AM | Business Wire | ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/10/2016 | 5:38AM | Business Wire | Incyte et ARIAD annoncent un accord dans le cadre duquel Incyte rachètera les opérations européennes d'ARIAD et vendra sou... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/09/2016 | 12:37PM | Business Wire | Incyte und ARIAD geben Vereinbarung zur Übernahme des europäischen Geschäfts von ARIAD durch Incyte und die Einlizenzierun... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/09/2016 | 7:17AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/09/2016 | 7:00AM | Business Wire | Incyte & ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations & In-license Iclusig® (ponatinib) in E... | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/06/2016 | 5:01PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/06/2016 | 4:59PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |
| 05/06/2016 | 4:55PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ARIA | Ariad Pharmaceuticals, Inc. |